These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25542901)

  • 1. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
    Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
    Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to ERBB3-Directed Targeted Therapy in
    Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
    Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
    [No Abstract]   [Full Text] [Related]  

  • 3. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
    Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
    J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S
    Adv Anat Embryol Cell Biol; 2007; 190():1-65. PubMed ID: 17432114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
    Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
    Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
    Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
    Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
    Miyake TM; Pradeep S; Bayraktar E; Stur E; Handley KF; Wu SY; Rodriguez-Aguayo C; Lee JS; Lopez-Berestein G; Coleman RL; Sood AK
    Mol Cancer Ther; 2020 Aug; 19(8):1727-1735. PubMed ID: 32499298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
    Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
    Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.
    Capparelli C; Rosenbaum S; Berman-Booty LD; Salhi A; Gaborit N; Zhan T; Chervoneva I; Roszik J; Woodman SE; Davies MA; Setiady YY; Osman I; Yarden Y; Aplin AE
    Cancer Res; 2015 Sep; 75(17):3554-67. PubMed ID: 26206558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER3 Is an Actionable Target in Advanced Prostate Cancer.
    Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
    Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
    Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of neuregulin and ErbB3 and ErbB4 after a traumatic lesion in the ventral funiculus of the spinal cord and in the intact primary olfactory system.
    Lindholm T; Cullheim S; Deckner M; Carlstedt T; Risling M
    Exp Brain Res; 2002 Jan; 142(1):81-90. PubMed ID: 11797086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
    Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK
    Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models.
    Zhang L; Castanaro C; Luan B; Yang K; Fan L; Fairhurst JL; Rafique A; Potocky TB; Shan J; Delfino FJ; Shi E; Huang T; Martin JH; Chen G; Macdonald D; Rudge JS; Thurston G; Daly C
    Mol Cancer Ther; 2014 May; 13(5):1345-55. PubMed ID: 24634416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
    Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
    Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
    Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
    Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
    Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
    Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.
    Ieguchi K; Fujita M; Ma Z; Davari P; Taniguchi Y; Sekiguchi K; Wang B; Takada YK; Takada Y
    J Biol Chem; 2010 Oct; 285(41):31388-98. PubMed ID: 20682778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.